Sangamo Therapeutics, Inc financial data

Symbol
SGMO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
501 Canal Blvd., Richmond, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
SANGAMO BIOSCIENCES INC (to 1/6/2017)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 247 % -15.7%
Debt-to-equity 65.1 % -14.3%
Return On Equity -40.4 % +10.5%
Return On Assets -156 % -581%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 179 M shares +4.12%
Common Stock, Shares, Outstanding 178 M shares +6.8%
Entity Public Float 229 M USD -63.8%
Common Stock, Value, Issued 2.04 M USD +18.6%
Weighted Average Number of Shares Outstanding, Basic 180 M shares +7.01%
Weighted Average Number of Shares Outstanding, Diluted 180 M shares +6.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 18.8 M USD -92.2%
Research and Development Expense 207 M USD -18.8%
General and Administrative Expense 54.8 M USD -16.9%
Operating Income (Loss) -344 M USD -149%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -333 M USD -163%
Income Tax Expense (Benefit) -5.17 M USD -1015%
Net Income (Loss) Attributable to Parent -328 M USD -158%
Earnings Per Share, Basic -1.88 USD/shares -129%
Earnings Per Share, Diluted -1.87 USD/shares -125%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 54.4 M USD -30.5%
Cash, Cash Equivalents, and Short-term Investments 81 M USD -73.7%
Accounts Receivable, after Allowance for Credit Loss, Current 691 K USD -90.2%
Assets, Current 68.6 M USD -69.8%
Property, Plant and Equipment, Net 22 M USD -63.2%
Operating Lease, Right-of-Use Asset 20.9 M USD -57%
Intangible Assets, Net (Excluding Goodwill) 0 USD -100%
Goodwill 0 USD -100%
Other Assets, Noncurrent 16.6 M USD -2.33%
Assets 129 M USD -70.7%
Accounts Payable, Current 15.5 M USD -22.3%
Accrued Liabilities, Current 18.5 M USD +20%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 40.2 M USD -30.4%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Deferred Income Tax Liabilities, Net 0 USD -100%
Operating Lease, Liability, Noncurrent 30.8 M USD -18.3%
Other Liabilities, Noncurrent 1.21 M USD -1.95%
Liabilities 72.3 M USD -31.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -5.8 M USD -0.75%
Retained Earnings (Accumulated Deficit) -1.46 B USD -29.1%
Stockholders' Equity Attributable to Parent 56.7 M USD -83.1%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 82.9 M USD -71.9%
Liabilities and Equity 129 M USD -70.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -48.7 M USD +26.6%
Net Cash Provided by (Used in) Financing Activities 22.1 M USD +176%
Net Cash Provided by (Used in) Investing Activities 35.8 M USD +0.31%
Common Stock, Shares Authorized 640 M shares 0%
Common Stock, Shares, Issued 178 M shares +6.8%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8.63 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 55.3 M USD -30.6%
Deferred Tax Assets, Valuation Allowance 351 M USD +16.4%
Deferred Tax Assets, Gross 357 M USD +9.97%
Operating Lease, Liability 38.1 M USD -11.6%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -328 M USD -160%
Lessee, Operating Lease, Liability, to be Paid 45.2 M USD -13.9%
Property, Plant and Equipment, Gross 77.9 M USD -22.1%
Operating Lease, Liability, Current 4.59 M USD +11.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.56 M USD +3.29%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.83 M USD -0.07%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.88 M USD -25%
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.54 M USD -0.19%
Deferred Tax Assets, Operating Loss Carryforwards 197 M USD +13%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5 M shares 0%
Unrecognized Tax Benefits 18.3 M USD +0.78%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.49 M USD -0.64%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.41 M USD -59.7%
Deferred Tax Assets, Net of Valuation Allowance 5.76 M USD -74.9%
Share-based Payment Arrangement, Expense 21.8 M USD -32.4%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%